New York Times |
AbbVie Inc To Shell Out $21 Billion For Pharmacyclics
InvestCorrectly AbbVie Inc (NYSE:ABBV) CEO, Richard Gonzalez, finally had his way, with Pharmcyclics, on Wednesday. After fending-off two other aggressive contenders, Gonzalez' fight-to-the-finish for the Imbruvica cancer drug has cost ABBVie close to $21 billion. Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of … Sell-Side Reaction On AbbVie Inc-Pharmacyclics, Inc. Deal: Is The M&A Bubble … AbbVie (ABBV) in Focus: Stock Falls by 5.7% |
SOURCE: Business – Google News – Read entire story here.